Magellan Biosciences is provider of point-of-care analyzers and automated systems for hospital-based labs and near-patient testing.
Lead poisoning threatens millions of people, yet is entirely preventable. Our mission is to help identify and protect those at risk.Magellan Diagnostics is a medical device company that provides point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing. Headquartered outside Boston in Billerica, Massachusetts, Magellan is dedicated to offering high-quality, reliable products that help identify children and adults at risk of harm due to lead exposure.Magellan Diagnostics has been a pioneer in the analysis of blood lead since the late 1960s, when the company (then called ESA, Inc.) was founded by four PhD graduates from the Massachusetts Institute of Technology (MIT). Applying a novel technique called Anodic Stripping Voltammetry (ASV), they designed and built a bench top analyzer for the measurement of lead in blood. The company then adapted this technology to create smaller, portable instruments that can be used outside of the traditional reference laboratory. This major achievement broadened the accessibility of lead testing by bringing it to the point of care.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 29, 2006 | Private Equity(PE) | $50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
New England Partners | — | Private Equity(PE) |